Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions
Mouhammad Jumaa, Aarón Rodríguez-Calienes, Giana Dawod, Juan Vivanco‐Suarez, Ameer E Hassan, Afshin A. Divani, Marion Oliver, Marc Ribó, Nils Petersen, Michael Abraham, Johanna T Fifi, Waldo R. Guerrero, Amer Malik, James E. Siegler, Thanh N. Nguyen, Sunil A. Sheth, Albert J. Yoo, Guillermo Linares, Nazli Janjua, Darko Quispe‐Orozco, Milagros Galecio‐Castillo, Cynthia Zevallos, Marco Málaga, Mudassir Farooqui, Tudor G. Jovin, Syed Zaidi, Santiago Ortega‐Gutiérrez
Topics & Concepts
CangrelorMedicineTirofibanEptifibatideInternal medicineOdds ratioRegimenIntraventricular hemorrhageGastroenterologyAnesthesiaMyocardial infarctionSurgeryPercutaneous coronary interventionP2Y12PregnancyBiologyGestational ageGeneticsCerebrovascular and Carotid Artery DiseasesPeripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular Diseases